We applied a combination of a forward genetic screen using CRISPR-dCas9 technology and the analysis of large-scale cancer genomics data sets from patients to identify molecules and signaling pathways that confer resistance to the CDK4/6 inhibitor Palbociclib in bladder cancer. Here, CDK4 is linked to cancer.